DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Remifentanil and Nitroprusside for Controlled Hypotension

Information source: Jeju National University School of Medicine
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypotension, Controlled

Intervention: remifentanil (Drug); nitroprusside (Drug)

Phase: N/A

Status: Completed

Sponsored by: Jeju National University School of Medicine

Summary

The purpose of this study is the comparison of the cardiovascular effects of remifentanil and nitroprusside for controlled hypotension

Clinical Details

Official title: The Comparison of the Cardiovascular Effects of Remifentanil and Nitroprusside for Controlled Hypotension

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Primary outcome: Cardiac index

Secondary outcome: Total peripheral resistance index

Eligibility

Minimum age: 20 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients who underwent endoscopic sinus surgery

Exclusion Criteria:

- patient who took any drug to influence this study

- patient with cardiovascular disease, renal disease or liver disease

Locations and Contacts

Jeju National University Hospital, Jeju-si, Jeju Special Self-Governing Province 690-767, Korea, Republic of
Additional Information

Starting date: June 2012
Last updated: December 3, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017